Achillion climbs on ACH-3102 data

By BC Staff | Feb 10, 2015 | 1:50 AM GMT

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) gained $0.84 to $11.66 on Monday after it said 100% of HCV genotype 1 patients receiving ACH-3102 plus

Read the full 228 word article

How to gain access

Continue reading with a
two-week free trial.